Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 2896, showing 100 per page
Biomarker NameUniProt IDPublicationConditionSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
UCHL1 P09936 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
UCHL1 P09936 Zhou et al. 2023 SO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
UBLCP1 Q8WVY7 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBL7 Q96S82 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
UBE2V2 Q15819 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
UBE2V2 Q15819 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
UBE2O Q9C0C9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBE2N P61088 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBE2N P61088 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
UBE2N P61088 Filareti et al. 2017 Late ALS – Early ALS PBMCs Down 4 Early-ALS, 4 Late-ALS 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
UBE2M P61081 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBE2L3 P68036 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBE2L3 P68036 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
UBE2H C9JZG9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBE2D3 P61077 Umoh et al. 2018 ALS – Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
UBE2D2 A0A0A0MQU3 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
UBC F5H265 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
UBASH3B Q8TF42 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
UBA52 P62987 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
UBA52 P62987 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
TXNL1 O43396 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TXNDC5 Q8NBS9 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
TXNDC17 Q9BRA2 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TXNDC12 O95881 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
TXN P10599 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TWSG1 Q9GZX9 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TWF2 Q6IBS0 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TUFM P49411 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TUBB6 Q9BUF5 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TUBB3 Q13509 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TUBB3 Q13509 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
TUBB2A Q13885 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TUBB P07437 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
TUBA4A P68366 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
TUBA1B P68363 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TTYH1 Q9H313 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TTR P02766 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TTR P02766 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
TTR P02766 Xu et al. 2018 ALS – Control Plasma Down 42 ALS, 18 control 61.8 ± 9.6
TTLL11 Q6ZUZ3 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
TTC9C Q8N5M4 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TTC5 Q8N0Z6 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
TTC1 Q99614 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
TSC22D1 Q15714 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TRIM43B A6NCK2 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
TRIM2 Q9C040 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TREM2 Q9NZC2 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TREM2 Q9NZC2 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
TPST1 O60507 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
TPPP3 Q9BW30 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPPP O94811 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
TPP1 O14773 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPM4 P67936 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPM4 P67936 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
TPM4 P67936 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
TPM4 P67936 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
TPM1 Q6ZN40 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPM1 P09493 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPM1 P09493 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
TPI1 P60174 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
TPI1 P60174 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TPD52L2 O43399 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TPD52 P55327 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TPD52 P55327 Englen-Lee et al. 2017 ALS – Control Spinal cord (PH & AH) Up 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6
TPD52 P55327 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TOPBP1 Q92547 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
TOLLIP Q9H0E2 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
TOLLIP Q9H0E2 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TNXB P22105 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
TNS1 Q9HBL0 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
TNR Q92752 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TNR Q92752 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TNR Q92752 Collins et al. 2015 ALS – Control CSF Down 90 ALS, 80 control
TNNT2 P45379 Berrone et al. 2023 fALS – Control Plasma Up 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
TNNT2 P45379 Berrone et al. 2023 ALS – Control Plasma Up 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
TNNT2 P45379 Berrone et al. 2023 sALS – Control Plasma Up 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
TNFSF9 P41273 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
TNFRSF1A P19438 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TNFRSF12A Q9NP84 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
TNC P24821 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TMPO P42167 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TMPO P42167 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
TMOD2 Q9NZR1 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TMEM9B Q9NQ34 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
TMEM9 Q9P0T7 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TMEM59 Q9BXS4 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TMEM55B G3V3P3 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TMEM33 P57088 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
TMEM30A Q9NV96 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TMEM30A Q9NV96 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
TMEM205 Q6UW68 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
TMEM132E Q6IEE7 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TMEM132D Q8N8D1 Vu et al. 2023 ALS fast – ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
TMED9 Q9BVK6 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
TMED5 Q9Y3A6 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
TMED4 Q7Z7H5 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
TM9SF4 Q92544 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
TLR4 O00206 Berrone et al. 2023 ALS – Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
TLN2 Q9Y4G6 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
TLN1 Q9Y490 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)